4.7 Article

Hypoxia-inducible factor 1-alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl-4-hydroxylase 2

Journal

JOURNAL OF PATHOLOGY
Volume 242, Issue 3, Pages 322-333

Publisher

WILEY
DOI: 10.1002/path.4906

Keywords

osteoclast; hypoxia-inducible factor (HIF); differentiation; bone resorption; PHD2

Funding

  1. UCB Pharma [R41281CN002]
  2. Nc3Rs [NC/L001403/1]
  3. MRC/NIHR EME [12/206/30]
  4. Wellcome Trust
  5. Ludwig Institute for Cancer Research
  6. Oxford BHF Centre for Research Excellence
  7. Arthritis Research UK [20631, MP/19200]
  8. Orthopaedic Research UK [509]
  9. Rosetrees Trust [M456]
  10. Oxford National Institute of Health Research (NIHR) Musculoskeletal Biomedical Research Unit (BRU)
  11. British Heart Foundation [FS/11/50/29038] Funding Source: researchfish
  12. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) [NC/M000133/1, NC/L001403/1] Funding Source: researchfish
  13. Rosetrees Trust [M456] Funding Source: researchfish
  14. Versus Arthritis [20631, 19200] Funding Source: researchfish

Ask authors/readers for more resources

Osteogenic-angiogenic coupling is promoted by the hypoxia-inducible factor 1-alpha (HIF-1 alpha) transcription factor, provoking interest in HIF activation as a therapeutic strategy to improve osteoblast mineralization and treat pathological osteolysis. However, HIF also enhances the bone-resorbing activity of mature osteoclasts. It is therefore essential to determine the full effect(s) of HIF on both the formation and the bone-resorbing function of osteoclasts in order to understand how they might respond to such a strategy. Expression of HIF-1 alpha mRNA and protein increased during osteoclast differentiation from CD14+ monocytic precursors, additionally inducing expression of the HIF-regulated glycolytic enzymes. However, HIF-1 alpha siRNA only moderately affected osteoclast differentiation, accelerating fusion of precursor cells. HIF induction by inhibition of the regulatory prolyl-4-hydroxylase (PHD) enzymes reduced osteoclastogenesis, but was confirmed to enhance bone resorption by mature osteoclasts. Phd2(+/-) murine osteoclasts also exhibited enhanced bone resorption, associated with increased expression of resorption-associated Acp5, in comparison with wild-type cells from littermate controls. Phd3(-/-) bone marrow precursors displayed accelerated early fusion, mirroring results with HIF-1 alpha siRNA. In vivo, Phd2(+/-) and Phd3(-/-) mice exhibited reduced trabecular bone mass, associated with reduced mineralization by Phd2(+/-) osteoblasts. These data indicate that HIF predominantly functions as a regulator of osteoclast-mediated bone resorption, with little effect on osteoclast differentiation. Inhibition of HIF might therefore represent an alternative strategy to treat diseases characterized by pathological levels of osteolysis. (C) 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available